• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Tanzeum (albiglutide)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Tanzeum (albiglutide)

  • Profile

Profile

Contact Information

Contact: GlaxoSmithKline
Website: https://www.gsk.com/en-gb/

Currently Enrolling Trials

    Show More

    General Information

    Tanzeum (albiglutide) is an agonist of the albumin-based glucagon-like peptide (GLP)-1 fusion protein. It augments glucose-dependent insulin secretion and slows gastric emptying.

    Tanzeum is specifically indicated as an adjunct to diet and exercise to improve glycemic control in adults with type II diabetes mellitus.

    Mechanism of Action

    Tanzeum (albiglutide) is a GLP-1 receptor agonist, a recombinant fusion protein comprised of 2 tandem copies of modified human GLP-1 genetically fused in tandem to human albumin. The human GLP-1 fragment sequence 7 36 has been modified with a glycine substituted for the naturally-occurring alanine at position 8 in order to confer resistance to dipeptidylpeptidase IV (DPP-IV) mediated proteolysis. The human albumin moiety of the recombinant fusion protein, together with the DPP-IV resistance, extends the half-life allowing once-weekly dosing.

    Side Effects

    Adverse effects associated with the use of Tanzeum may include, but are not limited to, the following:

    • Upper respiratory tract infection
    • Diarrhea
    • Nausea
    • Injection site reaction

    Dosing/Administration

    Tanzeum is supplied as a solution for subcutaneous injection. The recommended dose is 30 mg once weekly given as a subcutaneous injection in the abdomen, thigh or upper arm region. The dosage may be increased to 50 mg once weekly if the glycemic response is inadequate. Tanzeum may be administered at any time of day without regard to meals. It should be administered once a week on the same day each week. The day of weekly administration may be changed, if necessary, as long as the last dose was administered four or more days before. If a dose is missed, Tanzeum should be administered as soon as possible within three days after the missed dose. Thereafter, dosing can resume on the usual day of administration. If it is more than three days after the missed dose, dosing should wait until the next regularly scheduled weekly dose.

    Clinical Trial Results

    FDA Approval
    The FDA approval of Tanzeum was based on a 52-week, randomized, double-blind, placebo-controlled, multicenter trial. A total of 296 subjects with type II diabetes inadequately controlled on diet and exercise were randomized Tanzeum 30 mg SC once weekly, Tanzeum 30 mg SC once weekly uptitrated to 50 mg once weekly at week 12, or placebo. Compared with placebo, treatment with Tanzeum 30 mg or 50 mg resulted in statistically significant reductions in HbA1c from baseline at week 52. The adjusted mean change in weight from baseline did not differ significantly between Tanzeum (-0.4 to -0.9 kg) and placebo (-0.7 kg) at week 52.

    Additional Information

    For additional information regarding Tanzeum or type II diabetes, please visit the Tanzeum web page.

    Approval Date: 2014-04-01
    Company Name: GlaxoSmithKline
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • SurveywBlueBackground-360x240.png

      Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

    • TrendsInsights2023-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Two

    • TimeMoneyEffort-360x240.png

      Time is Money and So Is Effort, Budgeting Experts Say

    • TrendsInsights2023A-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Three

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing